Evidence map›Paper›PMID 40151419›Full record

ArticleOncology letters2025

Personalized combination therapy for diffuse midline glioma: A case report.

Mengqi Sun, Jizhou Zheng, Long Gong, Zihuang Li, Lijun Wang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mengqi SunDepartment of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong 518000, P.R. China.
Jizhou ZhengDepartment of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong 518000, P.R. China.
Long GongDepartment of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong 518000, P.R. China.
Zihuang LiDepartment of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong 518000, P.R. China.
Lijun WangDepartment of Radiation Oncology, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, Guangdong 518000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to analyze the efficacy of personalized combination therapy for patients with H3K27M mutant diffuse midline glioma (DMG) so as to explore new treatment options for further clinical research. The clinical data and prognosis of a patient with H3K27M mutant DMG are summarized and discussed in the context of the relevant literature. The patient was a 20-year-old female diagnosed with DMG treated with a combination of surgery, radiotherapy, chemotherapy, electric field therapy, immunotherapy and targeted therapy. An overall survival time of 28 months was achieved. In summary, personalized treatment strategies are expected to provide longer-lasting survival benefits for patients with DMG.

Indexed as

comprehensive treatmentdiffuse midline gliomaH3K27M mutationlong-term survival

Identifiers

PMID40151419
PMCPMC11948954

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.